Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.63 |
| ▸ | PPARG | P37231 | 11/20 | 0.63 |
| ▸ | PPARA | Q07869 | 10/20 | 0.63 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10219451 | 0.90 | PPARD (0.77) | PPARDPPARGPPARAPCSK9 | |
| SCHEMBL10219437 | 0.90 | PPARD (0.77) | PPARDPPARGPPARAPCSK9 | |
| SCHEMBL10219459 | 0.88 | PPARD (0.64) | PPARDPPARGPPARAPCSK9CYP2D6 | |
| SCHEMBL10219445 | 0.87 | PPARG (0.48) | PPARDPPARGPPARA | |
| SCHEMBL10219630 | 0.87 | PPARD (0.64) | PPARDPPARGPPARAPCSK9CYP2D6 | |
| SCHEMBL10220667 | 0.86 | PPARD (0.80) | PPARDPPARGPPARA | |
| SCHEMBL10219433 | 0.86 | PPARD (0.74) | PPARDPPARGPPARAPCSK9 | |
| SCHEMBL10219947 | 0.85 | PPARD (0.62) | PPARDPPARGPPARAPCSK9CYP2D6 | |
| SCHEMBL10271106 | 0.85 | PPARD (0.60) | PPARDPPARGPPARAPCSK9CSNK1D | |
| SCHEMBL10219443 | 0.85 | PPARD (0.77) | PPARDPPARGPPARAPCSK9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | PPARD 1/4885PPARG 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.